Free Access
Med Sci (Paris)
Volume 24, Number 2, Février 2008
Page(s) 215 - 218
Section Dernière heure
Published online 15 February 2008
  1. Van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357 : 2677–86. [Google Scholar]
  2. Kaplan JC, Delpech M. Biologie moléculaire et médecine, 3e ed. Paris : Flammarion Médecine-Sciences, 2007 : 401–16. [Google Scholar]
  3. Van Deutekom JC, Van Ommen G. Advances in Duchenne muscular dystrophy gene therapy. Nat Med 2003; 4 : 774–83. [Google Scholar]
  4. Goyenvalle A, Vulin A, Fougerousse F, et al. Le saut d’exon thérapeutique : un espoir pour les dystrophinopathies. Med Sci (Paris) 2004; 20 : 1163–5. [Google Scholar]
  5. Benchaouir R, Meregalli M, D’Antonio G, et al. Réhabilitation de la dystrophine humaine dans le modèle scid/mdx après greffe de cellules souches de patients DMD corrigées par saut d’exon. Med Sci (Paris) 2008; 24 : 99–101. [Google Scholar]
  6. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2 : 90–5. [Google Scholar]
  7. England S, Nicholson L, Johnson M, et al. Very mild muscular dystrophy associated with the deletion of 46 % of dystrophin. Nature 1990; 343 : 180–2. [Google Scholar]
  8. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin : implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8 : 253–61. [Google Scholar]
  9. Van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10 : 1547–54. [Google Scholar]
  10. Aartsma-Rus A, Janson AA, Kaman WE, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004; 74 : 83–92. [Google Scholar]
  11. Aartsma-Rus A, Kaman WE, Weij R, et al. Exploring the frontiers of therapeuticexon skipping for Duchenne muscular dystrophy by double targetingwithin one or multiple exons. Mol Ther 2006; 14 : 401–7. [Google Scholar]
  12. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306 : 1796–9. [Google Scholar]
  13. Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005; 102 : 198–203. [Google Scholar]
  14. McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006; 13 : 1373–81. [Google Scholar]
  15. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12 : 175–7. [Google Scholar]
  16. Benchaouir R, Meregalli M, Farini A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stemcells into dystrophic mice. Cell Stem Cell 2007; 1 : 644–57. [Google Scholar]
  17. Béroud C, Tuffery-Giraud S, Matsuo M, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63 % of patients with Duchenne muscular dystrophy. Hum Mutat 2007; 28 : 196–202. [Google Scholar]
  18. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447 : 87–91. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.